Therapeuticdiscovery
Biosimilar Ustekinumab
Originator: Stelara (Janssen)
Biosimilar program of Ustekinumab (Stelara), an IL-12/IL-23 inhibitor for psoriasis and inflammatory bowel disease.
Indications
- Plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
Overview
Ustekinumab (originator: Stelara) targets the p40 subunit shared by IL-12 and IL-23. IMGENEX India is in the early discovery phase of a biosimilar version.
Contact us today to learn more about this product. You can also email us at info@imgenexindia.com.